Aeglea BioTherapeutics (AGLE) is Initiated by Wells Fargo to Outperform

Aeglea BioTherapeutics (AGLE) was Initiated by Wells Fargo to “Outperform”. Wells Fargo advised their investors in a research report released on May 2, 2016.

In a different news, on Apr 12, 2016, Anthony Quinn (director) purchased 10,000 shares at $10.00 per share price. According to the SEC, on Apr 12, 2016, Russell J. Cox (director) purchased 7,000 shares at $10.00 per share price.

Aeglea BioTherapeutics

Leave a Reply

Aeglea BioTherapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Aeglea BioTherapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.